Ascentage Pharma: Trustee Acquires 50,000 Shares to Fund 2022 RSU Scheme Vesting

Bulletin Express

Sep 28

Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through on-market transactions. The acquisition is intended to satisfy RSUs as they vest under the scheme.

The purchase was executed at an average price of HK$28.56 per share, bringing the cash consideration to HK$1.43 million, excluding related expenses. The newly acquired shares represent approximately 0.01 % of Ascentage Pharma’s total issued share capital.

Following the transaction, the trustee’s aggregate holding dedicated to the 2022 RSU Scheme increased to 2.72 million shares. In accordance with the scheme’s rules and the trust deed, the trustee will not exercise voting rights attached to these shares.

The company reiterated that no additional RSU awards have been granted beyond the initial grant on 23 June 2022 and subsequent grants made on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, 20 April 2026, and 29 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1120046684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120046684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120046684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-28 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120046684","market":"hk","top_or_hot":-1,"title":"Ascentage Pharma: Trustee Acquires 50,000 Shares to Fund 2022 RSU Scheme Vesting","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through on-market transactions. The acquisition is intended to satisfy RSUs as they vest under the scheme.</p>\n<p>The purchase was executed at an average price of HK$28.56 per share, bringing the cash consideration to HK$1.43 million, excluding related expenses. The newly acquired shares represent approximately 0.01 % of Ascentage Pharma’s total issued share capital.</p>\n<p>Following the transaction, the trustee’s aggregate holding dedicated to the 2022 RSU Scheme increased to 2.72 million shares. In accordance with the scheme’s rules and the trust deed, the trustee will not exercise voting rights attached to these shares.</p>\n<p>The company reiterated that no additional RSU awards have been granted beyond the initial grant on 23 June 2022 and subsequent grants made on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, 20 April 2026, and 29 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma: Trustee Acquires 50,000 Shares to Fund 2022 RSU Scheme Vesting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma: Trustee Acquires 50,000 Shares to Fund 2022 RSU Scheme Vesting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-28 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through on-market transactions. The acquisition is intended to satisfy RSUs as they vest under the scheme.</p>\n<p>The purchase was executed at an average price of HK$28.56 per share, bringing the cash consideration to HK$1.43 million, excluding related expenses. The newly acquired shares represent approximately 0.01 % of Ascentage Pharma’s total issued share capital.</p>\n<p>Following the transaction, the trustee’s aggregate holding dedicated to the 2022 RSU Scheme increased to 2.72 million shares. In accordance with the scheme’s rules and the trust deed, the trustee will not exercise voting rights attached to these shares.</p>\n<p>The company reiterated that no additional RSU awards have been granted beyond the initial grant on 23 June 2022 and subsequent grants made on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, 20 April 2026, and 29 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1120046684","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120046684","pubTimestamp":1790606527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"亚盛医药：受托人收购 50,000 股股份以资助 2022 年受限制股份单位计划归属","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International (Ascentage Pharma) reported that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 50,000 existing shares on 28 September 2026 through on-market transactions. The acquisition is intended to satisfy RSUs as they vest under the scheme.\nThe purchase was executed at an average price of HK$28.56 per share, bringing the cash consideration to HK$1.43 million, excluding related expenses. The newly acquired shares represent approximately 0.01 % of Ascentage Pharma’s total issued share capital.\nFollowing the transaction, the trustee’s aggregate holding dedicated to the 2022 RSU Scheme increased to 2.72 million shares. In accordance with the scheme’s rules and the trust deed, the trustee will not exercise voting rights attached to these shares.\nThe company reiterated that no additional RSU awards have been granted beyond the initial grant on 23 June 2022 and subsequent grants made on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, 20 April 2026, and 29 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}